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suffered from coronary heart disease (including stable angina pecto-
ris, unstable angina pectoris and acute myocardial infarction) and 80
healthy people from January 2013 to December 2014 were detected.
The data were analyzed by SPSS 21.0.
RESULTS The levels of serum CRP was 13.053.68mg/L and blood Hcy
was 21.178.63 mmol/L in patients with coronary heart disease were
higher than those in the control group(5.021.60 g/L, 8.152.03
mmol/L), the differences were statistically signiﬁcant(P <0.05). The
levels of serum CRP and blood Hcy in the acute myocardial infarction
subgroup of coronary heart disease patients(19.623.03 mg/L,
32.107.02 mmol/L) were higher than those in the unstable angina
pectoris subgroup(12.986.11 mg/L, 20.826.04 mmol/L)(P <0.05);
while, the levels of serum CRP and blood Hcy in the unstable pectoris
angina subgroup were higher than those in the stable angina pectoris
subgroup[(7.654.81) mg/L,(14.014.30) mmol/L], the differences
were statistically signiﬁcant (P <0.05).
CONCLUSIONS The levels of serum CRP and blood Hcy are high
expression in patients with coronary heart disease, and their expres-
sion level can be used as predictors to prompt the severity and type of
coronary heart disease.
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OBJECTIVES Explore the levels of peripheral blood CD144þ / Annexin
Vþ EMPs, EPCs in patients of acute coronary syndrome (ACS) with or
without diabetes during long-term follow-up. Disscuss the relation-
ship among EMPs, EPCs, coronary artery acute ischemic events and
Abnormal glucose metabolism.
METHODS Study included 66 patients with acute coronary syndrome
(ACS) according to the coronary angiography. Based on clinical
symptoms and cardiac marker levels, the patients were divided into two
groups, A group:diabetes mellitus, acute coronary syndrome (ACS)
(n¼45), B group: acute coronary syndrome (ACS) (n¼21). Two groups of
patients were given drug treatment and atorvastatin and followed up
for 6 months. Respectively, test the levels of CD144þ Annexin Vþ
EMPs, EPCs in peripheral blood and clinical indexes, the presence of
ischemic symptoms before and after the follow-up.
RESULTS During the 6 months follow-up, all of the patients have no
abnormally elevated myocardial markers, sudden death due to coro-
nary heart disease (CHD) and again revascularization readmission to
the hospital clinical events. The level of CD144þ / Annexin Vþ EMPs
has no signiﬁcant difference before and after follow-up between the
two groups. However, no matter A or B, the level of CD144þ / Annexin
Vþ EMPs before follow-up was signiﬁcantly higher than after follow-
up (P < 0.05), and before and after follow-up there is no correlation
between glycosylated hemoglobin and EMPs in group A. The level
of EPCs of group A was signiﬁcantly higher than that of group B
(P < 0.05), and it was positively correlated to glycosylated hemoglobin
(r¼0.457). After follow-up, The level of EPCs of group A was signiﬁ-
cantly lower than that of group B (P < 0.05), and it was negative
correlated to glycosylated hemoglobin (P < 0.05, r ¼ -0.365). However,
no matter A or B, the level of EPCs before follow-up was signiﬁcantly
higher than after follow-up (P < 0.05).
CONCLUSIONS No matter combining diabetes mellitus or not, acute
ischemic events caused endothelial dysfunction is the dominant factor of
peripheral blood EMPs levels, also the main cause of activating repair
mechanisms to promote EPC mobilization. Diabetes patients in acute
coronary events release more EPCs, which are positively related with
glycosylated hemoglobin levels. But when atherosclerotic plaque turns to
stable, the ability of repairing is much lower in patients with diabetes,
and has negative correlation with glycosylated hemoglobin levels
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Adiponectin stabilizes aortic plaques in ApoE-/- mice via regulating the
level of autophagy
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OBJECTIVES Adiponectin (APN), an adipose-derived adipokine, offers
anti-atherogenic effects although the precise mechanism remains un-
clear. Autophagy reported as the major intracellular degradation systemcan be induced in stress conditions, such as atherosclerosis and oxida-
tive stress. This study was designed to examine the correlation between
APN and autophagy in apolipoprotein E-deﬁcient (ApoE-/-) mice.
METHODS Adult ApoE-/- mice were fed a high fat diet for 12 weeks.
After 8 week feeding, mice were treated with 10 ug/kg APN or vehicle
every day for 4 weeks. The size of aortic plaque was measured by oil
red O staining and autophagosomes were detected by transmission
electron microscope. Western blot was used to evaluate the expres-
sion of autophagy maker protein, LC3II.
RESULTS The size of aortic plaque was reduced by APN. And the
levels of autophagosomes decreased in APN group compared with
control group. Furthermore, APN also decreased LC3II and LC3II/I
protein expression ratio.
CONCLUSIONS These data suggest the autophagy in ApoE-/- mice
caused by high diet could be ameliorated by APN.
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OBJECTIVES Renalase is a novel secretory amino oxidase and expressed
in kidney and heart. To research the protective mechanism of renalase in
local heart tissue, we established the low-expression renalase model with
lentivirus-mediated RNA interference technology.
METHODS Three renalase-targeting oligonucleotides were designed
after analyzing the mRNA of renalase. Lentivirus particles were pre-
pared by LV expression Systems (using the trono 3 plasmid component
system), and then, LV-RNLS-shRNAs and LV-NC-shRNA were respec-
tively transfected into H9C2 cells in different culture dishes. The
optimal oligonucleotide was screened by real-time PCR and western
blotting. The renalase gene low-expression in the heart tissue of rats
via pericardial cavity injection. And real-time PCR andwestern blotting
were used to detect renalase gene expression in the heart.
RESULTS In the cell screening experiment, the efﬁcacy of the inhibition
of renalase mRNA expression was 93.7%, and that of renalase protein
expression was 83.1% in H9C2 cells. When the oligonucleotide was
injected into the pericardial cavities of the SD rats on the 10th day, it
inhibited 63.9% of the expression of renalase protein in the heart tissues.
CONCLUSIONS LV-Rnls-RNAi (19813-1) can be used to establish an
optimal renalase low-expression model for the subsequent experiments.OTHERSOTHERS
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OBJECTIVES The relative efﬁcacy and safety of non-vitamin K antag-
onist oral anticoagulants(NOACs) against warfarin have been assessed
for stroke prevention in atrial ﬁbrillation(AF) in several clinical sub-
groups. However, no pooled analysis has been undertaken across the
four landmark phase 3 randomized controlled trials (RCTs) to assess the
effects of all NOACs against warfarin in the subgroup of patients with AF
and heart failure (HF). We performed a systemic review and meta-
analysis of RCTs to determine the relative efﬁcacy and safety of NOACs
against warfarin among subgroup patients with AF and HF. Additionally,
we compared outcomes between AF patients with HF and without HF.
